- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions
European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaena
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide
| EU orphan designation number: | EU/3/15/1560
|
| Active ingredient: | N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide |
| Indication: | Treatment of Duchenne muscular dystrophy |
| Sponsor: | FGK Representative Service GmbH
Heimeranstraße 35, D-80339 München, Deutschland |
Public summary of scientific opinion
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 13/10/2015 | Orphan designation | EMA/OD/109/15 | (2015)7031 of 09/10/2015 |
CONTACT
EU links
Directorate General Health & Consumers